AstraZeneca shareholders have approved a plan to unify the company's share listing structure across London, Stockholm, and New York.
The proposal to adopt new articles of association was passed with 99.36% of votes in favor at a general meeting on Monday, the company announced.
The move will upgrade the British drugmaker's U.S. presence by replacing its American Depositary Receipts on Nasdaq with a direct listing of ordinary shares on the New York Stock Exchange.
According to the company, the new structure is designed to provide flexibility to access a broader pool of capital.
"Today's significant vote in favour of the Board's proposal demonstrates strong shareholder support for AstraZeneca's harmonised listing structure in London, Stockholm and New York," said Chair Michel Demaré.
"Our new structure will offer the flexibility to access the broadest available pool of capital, including in the US, enabling more shareholders to participate in AstraZeneca's exciting future."
The company expects to terminate its ADR program and begin trading its shares on the NYSE by Feb. 2, 2026.
AstraZeneca confirmed it will remain headquartered, listed, and tax resident in the U.K.
More from this issuer
Related coverage
AstraZeneca on Thursday detailed its plan to invest $50 billion in the U.S. by 2030 and an agreement with the government to lower some drug prices, as it reported a 10% rise in revenue for the first nine months of the year.
AstraZeneca PLC and Amgen Inc. said Wednesday their drug Tezspire has been approved in the European Union to treat a chronic inflammatory nasal condition.
AstraZeneca and Amgen said Monday their drug Tezspire has been approved in the U.S. as a treatment for a chronic inflammatory nasal condition.
AstraZeneca's lupus drug Saphnelo has been recommended for approval in the European Union in a new, more convenient self-administered form.